Patent References
3001988
3300523
Antiandrogenic agents and method for the treatment of androgen dependent disease states Patent #: 3995060
Peptides having LH-RH/FSH-RH activity Patent #: 4024248
Method of treating benign prostatic hypertrophy Patent #: 4055641
Anti-androgenic steroids Patent #: 4087461
Polypeptide Patent #: 4100274
Peptides having gonadoliberin activity and process for their manufacture Patent #: 4118483
Methods for the treatment of hirsutism Patent #: 4139638
Antiandrogenic agents and methods for the treatment of androgen dependent disease states Patent #: 4161540
More ...
N-substituted-17ଲ-carbamoylandrost-4-en-3-one 5 reductase inhibitors Patent #: 4191759
Preparation of 4-aza-17-substituted-5-androstan-3-ones useful as 5-reductase inhibitors Patent #: 4220775
Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis Patent #: 4235893
Antiandrogenic agents and methods for the treatment of androgen dependent disease states Patent #: 4329364
4-Aza-17ଲ-substituted-5-androstan-3-one-reductase inhibitors Patent #: 4377584
Anti-androgenic amide derivative Patent #: 4386080
Treatment method Patent #: 4472382
Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists Patent #: 4481190
Novel 11ଲ-substituted-19-nor-steroids Patent #: 4547493
Novel 11 beta-substituted-19-nor-steroids Patent #: 4634696
Steroid derivatives Patent #: 4659516
Method of treatment of prostate cancer Patent #: 4659695
Phenol derivatives Patent #: 4732912
Phenol derivatives Patent #: 4751240
Combination therapy for selected sex steroid dependent cancers Patent #: 4760053
Ether and ester derivatives of phenols Patent #: 4760061
4-substituted 6-alkylidenandrosteine-3,17-dione derivatives and process for their preparation Patent #: 4822528
17 -Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors Patent #: 4859681
Phenol derivatives Patent #: 4904661
Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase Patent #: 4937237
Phenol derivatives Patent #: 5021414
Combination male breast cancer therapy Patent #: 5023234
Phosphinic acid substituted steroids as inhibitors of steroid 5-reductase Patent #: 5026882
Methods for treatment of male-pattern baldness Patent #: 5053403
Intermediate for making 3-oxo-4-aza-androst-1-ene 17ଲ-ketones Patent #: 5061801
17ଲ-aminobenzoyl-4-aza-5-androst-1-en-3-ones as benign prostatic hypertrophy agents Patent #: 5061802
Process for making 17-beta alkanoyl 3-oxo-4-aza-5--androst-1-enes Patent #: 5061803
Combination therapy for selected sex steroid dependent cancers Patent #: 5064813
Estrogen nucleus derivatives for use in inhibition of sex steroid activity Patent #: 5204337
Process for producing 7ଲ-substituted-aza-5댚ndrostan-3-ones Patent #: 5237064
Inventors
Assignee
Application No. 196332 filed on 02/14/1994
US Classes: 514/284 ,
Tetracyclo ring system having the six-membered hetero ring as one of the cyclos 514/859 ,
Acne 514/864 Seborrhea
Examiners Primary:
Jordan, Kimberly
Attorney, Agent or Firm
Foreign Patent References 10669/88 AU. 07/13/1988 10778/88 AU. 08/13/1988 31569/89 AU. 09/13/1989 0855992 BE. 10/13/1977 0970692 CA. 07/13/1975 052799 EP. 10/13/1981 58481 EP. 08/13/1982 0314199 EP. 02/13/1985 0155096 EP. 02/13/1985 138504 EP. 04/13/1985 160508 EP. 11/13/1985 163416 EP. 12/13/1985 0200859 EP. 11/13/1986 0271219 EP. 11/13/1987 0277002 EP. 01/13/1988 166509 EP. 01/13/1988 0294937 EP. 05/13/1988 298652 EP. 06/13/1988 0271220 EP. 06/13/1988 0285383 EP. 10/13/1988 375351 EP. 12/13/1989 375347 EP. 06/13/1990 375349 EP. 06/13/1990 414491 EP. 08/13/1990 414490 EP. 08/13/1990 414529 EP. 08/13/1990 427434 EP. 05/13/1991 435321 EP. 07/13/1991 458207 EP. 11/13/1991 1465544 FR. 01/13/1967 7022461 FR. 06/13/1970 0883091 FR. 05/13/1980 2529969 DE. 01/13/1976 3339295 DE. 05/13/1984 83545 LU. 10/13/1981 137542 NZ. 09/13/1967 142112 NZ. 06/13/1968 123341 NZ. 09/13/1970 181107 NZ. 11/13/1978 182661 NZ. 07/13/1979 201536 NZ. 08/13/1982 206745 NZ. 01/13/1984 207413 NZ. 11/13/1984 211145 NZ. 02/13/1985 213652 NZ. 09/13/1985 222883 NZ. 12/13/1987 208441 NZ. 01/13/1988 214798 NZ. 09/13/1988 214998 NZ. 06/13/1989 223262 NZ. 08/13/1989 222103 NZ. 08/13/1989 237023 NZ. 02/13/1991 8601105 WO. 02/13/1986 8705216 WO. 09/13/1987 9100732 WO. 01/13/1991 9112261 WO. 08/13/1991 9113060 WO. 09/13/1991
International Class A61K 031/44
Abstract Inhibitors of testosterone 5-reductase activity, for example those of formula: ##STR1## wherein novel substituents are provided at the R4, R6, R7, R17 and/or R17ଲ positions are useful for the treatment of diseases whose progress is aided by activation of androgen receptors, e.g., prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, androgenic alopecia and the like.
Other References Voigt et al., Endo, (1973), 92(4), pp. 1216-1922 Green et al., Nature, 320(13) Mar. 1986, pp. 134-139 Lubahn et al., Science, (1988) 240 pp. 327-330 Lubahn et al. Proc. Natl Acad. Sci. USA 86, 9534-9538, Dec. 1989 Neri et al., J. Steroidal Biochem., 1975, (6), pp. 815-819 Chang, et al., Biochemistry, 1982, 21(17) 4302-4109 Gyorki, et al., J. Steroidal Biochem. 25(3), 355-358, 1986 Macaulay, et al., J. Steroidal Biochem. 26(5) 535-538, 1987 Grunwell, et al., Steroids, 27(6), 1976, pp. 759-771 Chin, et al., J. Biol. Chem., 250(19), 1975, pp. 1682-1686 Auchus et al., Biochemistry, 1986, 25, 7295-7300 Schwarz, Organic Synthesis Collective, vol. 3: 332-333 (1955) Cooke, Jr.., Tetrahedron Letters, 22 pp. 1983-1986, 191 Gibson, et al., Angew Chem. Int. Ed. 7 (1968) No. 12, pp. 919-930 Raucher, et al., J. Org. Chem., 1981, 46, 3558-3559 Weiss, et al., Angew Chem. Int. Ed. 12 (1973) No. 10, p. 841 Bull, et al., Chem. Soc. Chem. Commun. 1986, pp. 451-453 Wang, et al., Can J. Chem., 65, 2121-2131, 1987 Jordan, et al., Endocrinology, 124 (4), 1989, pp. 1717-1726 Musto, et al., Endo. Res. Comm. (1977), vol. 4, No. 2, pp. 141-158 Solo, et al., Steroids, vol. 40, No. 6 (1982), pp. 603-614 De Larminat, et al., The Prostate, vo. 5 (1984), pp. 123-140 Beardwell, et al., (1983) Cancer Chemother. Pharmacol. 10, No. 3, 158-160 Brooks, et al., (1982) The Prostate, 3, No. 1, 35-44 Bruchovsky, et al., (1968) J. Biol. Chem. 243, No. 8, 2012-2021 Coy, et. al., (1982) Endocrinology, 110, 1445-1447 Debruyne, F. (1988) Bailliere's Clin. Oncol. Int'l. Practice & Res., pp. 559-570 Gohring et al., World Patent Information, vol. 11, No. 1., pp. 5-10, 1988 Salman, et al., J. Steroid Biochem, vol. 33, No. 1, pp. 25-31 (1989) Lefebvre, et al. Prostate 1982, 3(6), 569-578 Lee et al., Steroids 22, 677-685, 1973 Mobbs, et al., 71th An. Meeting of the Endocrine Soc., No. 1410, 1989 Mobbs et al., J. Steroidal Biochem., 19(3), 1279-1290, 1983 Donnelly, "Continuous Subcutaneous Administration of `Zoladex` (ICI 118,630--An LH-RH Analogue) to Patients with advanced Prostatic Cancer", ICI Pharmaceuticals Division, Macclesfield, U.K., 1988 Tora, et al. EMBO 8(7) 1981-1986, 1989 Nayfeh, et al., Steroids 14:3, 1969, pp. 269-283 Luthy, et al., J. Steroid Biochem. 31(5) 845-52, 1988 Labrie, et al., The Prostate, 4, 579-594, 1983 Begin, et al., Molecular and Cellular Endocrinology, 58 (1988) 213-219 Lee et al., J. Androl. 2(6) 293-299, 1981 Belis et al., J. Androl. 4, 144-149, 1983 Schally, et al., Cancer Treatment Reports, 68(a), 281-288 (1984) Levesque, et al., J. Med. Chem. 1991, 34 1624-1630 Santen, et al. LHRH and Its Analogues, MTP Press, pp. 351-364, (1984) Labrie et al., J. Steroid Biochem. 19(1) 999-1007, 1983 Labrie, et al., (1984) 7th International Congress of Endocrinology 1984, p. 98 Lambert, et al., (1986) Ann. Clin. Biochem., 23, 225-229 Potts, et al., (1978) Steroids, 32, No. 2, 257-267 Wilson, J. (1975) Handbk of Physio., Sec. 7, Endo. V, Amer. Physio. Soc. pp.491-508 Farnsworth, W. E. (1969) Investigative Urology, 6, No. 4, 423-427 Groom, et al., (1971) Biochem. J., 122, 125-126 Geller, et al., (1989) 71st Ann. Endo. Soc. Meet. (Seattle, 6/21-24). No. 1640, p. 432 Gormley, et. al., (1989) 71st Ann. Endo. Soc. Meet. (Seattle, 6/21-24). No. 1225, p. 329 Wagner, et al., (1975) Acta Endocr. (Kbh), Suppl. 193, 52 (abst) Robinson, et al., (1984) J. Steroid Biochem., 21, No. 5, 601-605 Swaneck, et al., (1982) Biochem. Biophysical Res. Comm., 106, No. 4, 1441-1447 Petrow, et al., (1982) J. Endocr., 95, 311-313 Kadohma, et al., (1985) J. Natl. Cancer Inst., 74, No. 2, 475-486 Earnshaw, et al., (1984) Clin. Invest., 21, 13-21 Corbin, et al., (1984) J. Steroid Biochem., 20 (6B), 1369, No. A9 Dutta et al., (1978) J. Med. Chem., 21, No. 10, 1018-1024 Erchegyi, et al., (1981) Blochem. & Biophysical Res. Comm. 100, No. 3, 915-920 Nestor, et al., (1984) J. Steroid Blochem., 20 (6B), 1366, No. A3 Faure, et al., LHRH and Its Analogs, pp. 337-349, 1988 Walsh, et al., The Journal of Clinical Investigation, vol. 57, Apr. 1976, pp. 1093-1097 Brooks, et al. Proc. of the Soc. for Exp. Biology and Medicine, 169, 67-73 (1982) George, et al., "The Effect of A 5--Reductase Inhibitor on Androgen Physiology in the Prepubertal Male Rat", 1165, Department of Cell Biology and Anatomy, University of Texas Southwestern Medical Center, Dallas, TX 75235, 1988 Tenover, et al., "Effects of 24-Week Administration of a 5-Alpha Reductase Inhibitor (MK-906) on Serum Levels of Testosterone (T), Free T, and Gonadotropins in Men", 583, Department of Medicine, University of Washintton, Seattle, WA 98103, 1988 Liang, et al., Endocrinology, vol. 112, No. 4, pp. 1460-1468, 1988 Sharpless, et al., Tetrahedron Letters, 1979 (1973) Riess, Institut de Chimie. Strasbourg, France (Jul. 31, 1964) Fujimoto, J. Pharm. Soc. Jap, 87:270 (1967) Toth, et al. (1982) J. Steroid Biochem 17:653-660 Junkmann, K. (1957) Recent Progr. Horm. Res., 13:1389-1427 Weinbauer, et al. (1986) Acta Endocrinologica 113:128-132 Seguin, et. al. Mol. Cell. Endocrinol., 21, 37-41 1981 Neumann et al., In: Clinics in Oncology, vol. 1, pp. 41-64, 1982 Simard, et al., Mol. Cell. Endocrinol., 44, 261-270, 1986 Poyet and Labrie, Mol. Cell. Endocrinol., 42, 283-288, 1985 Furr, et al. J. Endocr., 113, R7-R9, 1987 Labrie, et al., Important Advances in Oncology, Philadelphia, pp. 193-217, 1985 Wakeling, et al. J. Endocr., 112, R7-R10, 1987 Wakeling, et al. J. Steroid Biochem., 30, 141-147, 1987 Bhatnager, et al. Biol. Chem. 253, 811-815, 1978 Chin, et al. J. Biol. Chem., 255, 3660-3664, 1980 Thomas, et al. J. Biol. Chem., 258, 1587-1590, 1983 Tobias, et al. J. Biol. Chem., 257, 2783-2786, 1982 Thomas, et al. J. Biol. Chem., 258, 11500, 1983 Labrie, et al. Endocrinology 123: 1412-1417, 1988 Plante, et al., J. Steroid Biochem., 31(1), 61-64 (1988) Rivier, et al., LHRH Analogs as Antiovulatory Agents, pp. 11-22, 1988 Nestor, Jr. et al., LHRH Agonists & Antagonists Containing . . . Amino Acids, pp. 23-33, 1988 Salman, et al., J. Steroid Biochem., 26, 383-391, 1987 Habenicht, et al., (1987) The Prostate, 11, 313-326 DeKlerk, et al., (1985), The Prostate, 7, 1-12 Redding, et al., (1983) Proc. Natl. Acad. Sci. USA, 80, 1457-1462 Kerle, et al., (1984) J. Steroid Biochem. 20 (6B), 1395, No. A61 Stewart, et al., (1969) In: Solid Phase Peptide Synthesis, Freeman and Co, San Francisco Coy, et al. (1976) J. Med. Chem., 19, No. 3, 423-425 Wenderoth, et al., (1983) Endocrinology, 113, No. 2, 569-573 McConnell, et al., (1989) The Journal of Urology, 141, 239A, No. 280 Stoner, E. (1989) Lecture: Role of 5-reductase inhibitor in BPH. AUA Today, Nov./Dec Toomey, et al. (1989) 71st Ann. Endo. Soc. Meet. (Seattle, 6/21-24). No. 1226, p. 329 Labrie, et al. (1987) J. Steroid Biochem., 28, No. 4, 379-384 Simard, et al., (1988) Molecular Endocrinology, 2, No. 9, 775-784 pp. 3-10 Moore, et al., (1979) J. Clin. Invest., 63, 351-357 Nestor, J. (1984) Devel. of agon. LHRH analogs, LHRH & its analogs, MTP Press Ltd Williams, et al. (1987) Cancer Treatment Reports, 71, No. 12, 1197-1201 Chan, et al., (1987) Biochemical Biophysical Research Communication, 144 (1) 166-171 Taylor, M. J. (1987) J. Endocr., 113, 489-493 Rivier, et al., (1984) J. Steroid Biochem., 20 (6B), 1365, No. A1 Labrie, et al., 157-200, Genitourinary Cancer. ISBN 0-89838-830-9 (1987) Stoner, E., J. Steroid Biochm. Molec. Biol., vol. 37, No. 3, pp. 375-378 (1990) Dorrenbos, N. J., et al., J. Pharm. Sci., 63: 620-21 (1974) "The Merck Index", PROSCAR (1989) p. 1250 Dorrenbos, N. J., Solomons, W. E., J. Pharm. Sci., 62:638-640 (1973) Kadohama, et al., Cancer Res., 44:4947-4954 (1984) Lan-Hargest, et al., Tetrahedron Letters, 28: 6117-6120 (1987) Liang, T., et al., J. Steroid Biochem., 256: 7998-8005 (1981) MacIndoe, et al., J. Steroid Blochem., 20: 1095-1100 (1984) Nakayama, et al., J. Antibiotics, XLII: 1235-1240 (1989) Nakayama, et al., J. Antibiotics, XLII: 1230-1234 (1989) Nakayama, et al., J. Antibiotics, XLII: 1221-1229 (1989) Petrow, et al., Steroids, 38:121-140 (1981) Petrow, et al., J. Steroid Biochem., 19:1491-1502 (1983) Solomons, et al., J. Pharm. Sci., 63:19-23 (1974) Andersson, et al., Nature, 354, pp. 159-161 (1991) Vermeulen, et al., The Prostate 14, pp. 45-53 (1989) di Salle, et al., "17ଲ-Acylurea Derivatives of 4-Azasteroids as inhibitors of Testosterone 5-Reductase", 1988 Weintraub, et al., J. Med. Chem., 28:831-833 (1985) Rasmusson, et al., J. Med. Chem. 1986, 29, pp. 2298-2315 Rasmusson, et al., J. Med. Chem., 1984, 27, pp. 1690-1701 Brooks, et al., Steroids 47/1, 1986 pp. 1-19 Levy, et al., Biochemistry 1990, vol. 29, pp. 2815-2824 Levy, et al. J. Steroid Blochem, vol. 34, Nos. 1-6, pp. 571-575, 1989 Holt, et al., J. Med. Chem., 1990, vol. 33 pp. 937-942 DIALOG Information Services; Biological abstracts retrieved 19 Jun. 1990; pp. 21 and 32 Metcalf, et al. TiPS; Dec. 1989 vol. 10 pp. 491-495 Rittmaster, et al., J. Clin. Endo. and Metabolism, vol. 65, No. 1 (1987) pp. 188-193 Brooks, et al., Endocrinology, (1961) vol. 109, No. 3, pp. 830-836 Andersson, et al., Proc. Natl. Acad. Sci. USA, vol. 87, pp. 3640-3644 (1990) Liang, et al., Endocrinology; 1985, vol;. 117, No. 2, pp. 571-579 Anderson, et al., Nature, vol. 219, Jul. 20, 1968, pp. 277-279 Liang, et al., J. Bio. Chem., vol. 259, No. 2 pp. 734-739 (1984) Imperato-McGinley, et al., Abst. 1639 Comparison of Plasma & Urinary . . . Deficiency, 1988 Doorenbos, et al., Chemistry and Industry, Oct. 1970, p. 1322 Doorenbos, et al., J. of Pharm. Sciences, vol 60, No. 8, (1971) pp. 1234-1235 Metcalf, et al., Tetrahedron Letters, vol. 21, pp. 15-18 (1980) STN International US Pat. Abs. 4,882,319 (pp. 6-7), 1988 Abstract of European Patent Appln. 294035, 1988 STN International; Abstract of U.S. Pat. No. 4,396,615, 1980 STN International; Abstract of European Patent Application No. 343,954, 1988 STN International; Abstract of British Patent No. GB 2,048,888, 1988 STN International; Abstract of U.S. Pat. No. 4,317,817, 1979 STN International; Abstract of European Patent No. 289327, 198
February 14, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
